Stephen A Hill
Insider
First SEC filing: Aug. 18, 2014 · Latest: Aug. 18, 2014
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Dec. 16, 2020 | LPCN | M | 7,500 | · | · | 12,750 Direct | +142.86% | Acquired | (price as of 2026-10-02) |
| Dec. 16, 2020 | LPCN | M | 7,500 | · | · | 7,500 Direct | · | Acquired | (price as of 2026-10-02) |
| June 24, 2020 | CLRB | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 10, 2020 | LPCN | A | 22,000 | $0.96 | $21,120 | 22,000 Direct | · | Acquired | -87.4% (price as of 2026-10-02) |
| June 4, 2020 | CLRB | P | 18,000 | $1.08 | $19,440 | 18,000 Direct | · | Acquired | -99.5% (price as of 2026-10-02) |
| June 13, 2019 | CLRB | A | 6,500 | · | · | 6,500 Direct | · | Acquired | (price as of 2026-10-02) |
| June 12, 2019 | LPCN | A | 10,000 | $1.68 | $16,800 | 10,000 Direct | · | Acquired | -92.8% (price as of 2026-10-02) |
| Nov. 29, 2018 | CLRB | S | 530 | $0.05 | $26 | 0 Direct | · | Acquired | -88.1% (price as of 2026-10-02) |
| Nov. 29, 2018 | CLRB | S | 9,390 | $0.10 | $939 | 0 Direct | · | Acquired | -94.1% (price as of 2026-10-02) |
| Nov. 29, 2018 | CLRB | S | 53 | $2.21 | $117 | 0 Direct | -100.00% | Disposed | -99.7% (price as of 2026-10-02) |
| Nov. 29, 2018 | CLRB | S | 939 | $2.21 | $2,075 | 53 Direct | -94.66% | Disposed | -99.7% (price as of 2026-10-02) |
| Oct. 12, 2018 | CLRB | A | 13,000 | · | · | 13,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 6, 2018 | GYRE | D | 190 | $10.07 | $1,913 | 1,190 Direct | -13.77% | Disposed | -95.3% (price as of 2026-10-02) |
| June 27, 2018 | LPCN | A | 20,000 | $1.33 | $26,600 | 20,000 Direct | · | Acquired | -90.9% (price as of 2026-10-02) |
| June 13, 2018 | GYRE | A | 5,000 | · | · | 5,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 20, 2018 | GYRE | J | 21,600 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Feb. 20, 2018 | GYRE | J | None | · | · | · Direct | · | Disposed | (price as of 2026-10-02) |
| Dec. 29, 2017 | LPCN | M | 2,500 | · | · | 6,500 Direct | +62.50% | Acquired | (price as of 2026-10-02) |
| Dec. 29, 2017 | LPCN | S 10b5-1 | 1,250 | $3.47 | $4,338 | 5,250 Direct | -19.23% | Disposed | -96.5% (price as of 2026-10-02) |
| Dec. 29, 2017 | LPCN | M | 2,500 | · | · | 7,500 Direct | -25.00% | Disposed | (price as of 2026-10-02) |
| July 13, 2017 | GYRE | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| May 31, 2017 | CLRB | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 26, 2017 | LPCN | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| July 5, 2016 | CLRB | A | 22,500 | $0.01 | $225 | 25,434 Direct | +766.87% | Acquired | -94.1% (price as of 2026-10-02) |
| June 14, 2016 | LPCN | A | 10,000 | $8.02 | $80,200 | 10,000 Direct | · | Acquired | -98.5% (price as of 2026-10-02) |
| June 9, 2016 | GYRE | A | 7,500 | · | · | 7,500 Direct | · | Acquired | (price as of 2026-10-02) |
| April 20, 2016 | CLRB | P | 9,390 | $0.01 | $94 | 9,920 Direct | +1771.70% | Acquired | -94.1% (price as of 2026-10-02) |
| April 20, 2016 | CLRB | P | 9,390 | $2.12 | $19,907 | 9,920 Direct | +1771.70% | Acquired | -100.0% (price as of 2026-10-02) |
| Dec. 17, 2015 | GYRE | P | 5,000 | $2.03 | $10,150 | 20,711 Direct | +31.82% | Acquired | -98.4% (price as of 2026-10-02) |
| Oct. 22, 2015 | GYRE | A | 6,750 | · | · | 6,750 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 22, 2015 | GYRE | A | 6,750 | · | · | 6,750 Direct | · | Acquired | (price as of 2026-10-02) |
| Oct. 22, 2015 | GYRE | A | 8,250 | · | · | 8,250 Direct | · | Acquired | (price as of 2026-10-02) |
| Aug. 28, 2015 | GYRE | F | 12,146 | $6.72 | $81,621 | 15,711 Direct | -43.60% | Disposed | -99.5% (price as of 2026-10-02) |
| Aug. 14, 2015 | GYRE | A | None | · | · | · Direct | · | Acquired | (price as of 2026-10-02) |
| June 16, 2015 | LPCN | A | 20,000 | · | · | 30,000 Direct | +200.00% | Acquired | (price as of 2026-10-02) |
| June 9, 2015 | CLRB | A | 5,000 | · | · | 5,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Nov. 13, 2014 | LPCN | P | 4,000 | $4.95 | $19,800 | 4,000 Direct | · | Acquired | -97.6% (price as of 2026-10-02) |
| Oct. 17, 2014 | GYRE | A | 175,000 | · | · | 195,000 Direct | +875.00% | Acquired | (price as of 2026-10-02) |
| Aug. 20, 2014 | CLRB | P | 5,300 | $0.01 | $53 | 21,351 Direct | +33.02% | Acquired | -99.4% (price as of 2026-10-02) |
| Aug. 20, 2014 | CLRB | P | 5,300 | $3.75 | $19,875 | 5,300 Direct | · | Acquired | -100.0% (price as of 2026-10-02) |
| Jan. 23, 2014 | GYRE | A | 175,000 | · | · | 175,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 6, 2014 | LPCN | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| March 11, 2013 | GYRE | P | 10,000 | $4.38 | $43,800 | 20,000 Direct | +100.00% | Acquired | -99.9% (price as of 2026-10-02) |
| March 11, 2013 | GYRE | P | 10,000 | $4.38 | $43,800 | 20,000 Direct | +100.00% | Acquired | -99.9% (price as of 2026-10-02) |
| March 8, 2013 | GYRE | P | 10,000 | $4.48 | $44,800 | 10,000 Direct | · | Acquired | -99.9% (price as of 2026-10-02) |
| March 8, 2013 | GYRE | P | 10,000 | $4.48 | $44,800 | 10,000 Direct | · | Acquired | -99.9% (price as of 2026-10-02) |
| Dec. 3, 2012 | GYRE | A | 400,000 | · | · | 400,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Dec. 16, 2020 | LPCN | Restricted Stock Unit | Common Stock | $0.00 | Jan. 25, 2027 | 7,500 | Acquired |
| June 24, 2020 | CLRB | Stock option (right to buy) | Common Stock | $1.28 | June 24, 2030 | 50,000 | Acquired |
| June 10, 2020 | LPCN | Stock Options (Right to Buy) | Common Stock | $0.96 | June 10, 2030 | 22,000 | Acquired |
| June 13, 2019 | CLRB | Stock option (right to buy) | Common Stock | $2.15 | June 13, 2029 | 6,500 | Acquired |
| June 12, 2019 | LPCN | Stock Option (Right to Buy) | Common Stock | $1.68 | June 12, 2029 | 10,000 | Acquired |
| Nov. 29, 2018 | CLRB | Warrants | Common Stock | $468.00 | Aug. 20, 2019 | 530 | Acquired |
| Nov. 29, 2018 | CLRB | Series A Warrants | Common Stock | $30.40 | April 20, 2021 | 9,390 | Acquired |
| Oct. 12, 2018 | CLRB | Stock option (right to buy) | Common Stock | $2.61 | Oct. 12, 2028 | 13,000 | Acquired |
| June 27, 2018 | LPCN | Stock Option (Right to Buy) | Common Stock | $1.33 | June 27, 2028 | 20,000 | Acquired |
| June 13, 2018 | GYRE | Stock Option (Right to Buy) | Common Stock | $24.94 | June 13, 2028 | 5,000 | Acquired |
| Feb. 20, 2018 | GYRE | Redeemable Convertible Note | Common Stock | · | · | 21,600 | Disposed |
| Feb. 20, 2018 | GYRE | Redeemable Convertible Note | Common Stock | · | · | · | Disposed |
| Dec. 29, 2017 | LPCN | Restricted Stock Unit | Common stock | $0.00 | Jan. 25, 2027 | 2,500 | Disposed |
| July 13, 2017 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | July 13, 2027 | 10,000 | Acquired |
| May 31, 2017 | CLRB | Stock option (right to buy) | Common Stock | $1.74 | May 31, 2027 | 10,000 | Acquired |
| Jan. 26, 2017 | LPCN | Restricted Stock Unit | Common Stock | · | Jan. 25, 2027 | 10,000 | Acquired |
| July 5, 2016 | CLRB | Stock option (right to buy) | Common Stock | $3.34 | July 5, 2026 | 22,500 | Acquired |
| June 14, 2016 | LPCN | Common Stock (right to buy) | Common Stock | $8.02 | June 13, 2026 | 10,000 | Acquired |
| June 9, 2016 | GYRE | Stock Option (Right to Buy) | Common Stock | $1.88 | June 9, 2026 | 7,500 | Acquired |
| April 20, 2016 | CLRB | Series A Warrants | Common Stock | $3.04 | April 20, 2021 | 9,390 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 6,750 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 6,750 | Acquired |
| Oct. 22, 2015 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.40 | Oct. 22, 2025 | 8,250 | Acquired |
| Aug. 14, 2015 | GYRE | Redeemable Convertible Note | Common Stock | $1.31 | · | · | Acquired |
| June 16, 2015 | LPCN | Stock Option (Right to Buy) | Common Stock | $7.29 | June 15, 2025 | 20,000 | Acquired |
| June 9, 2015 | CLRB | Stock option (right to buy) | Common Stock | $2.64 | June 9, 2025 | 5,000 | Acquired |
| Aug. 20, 2014 | CLRB | Stock purchase warrant (right to buy) | Common Stock | $4.68 | Aug. 20, 2019 | 5,300 | Acquired |
| Jan. 23, 2014 | GYRE | Stock Option (Right to Buy) | Common Stock, $0.001 par value per share | $4.74 | Jan. 22, 2024 | 175,000 | Acquired |
| Jan. 6, 2014 | LPCN | Stock Option (Right to Buy) | Common Stock | $8.25 | Jan. 6, 2024 | 10,000 | Acquired |
| Dec. 3, 2012 | GYRE | Stock Option (Right to Buy) | Common Stock | $4.50 | Dec. 2, 2022 | 400,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 10 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 3,750 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 3,750 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 3,750 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 7,500 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 26 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 26 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 13 | Direct |
| Aug. 18, 2014 | CLRB | Stock Option (right to buy) | 49 | Direct |
| Jan. 8, 2014 | LPCN | Common Stock | 0 | Direct |
| Dec. 5, 2012 | GYRE | No securities are beneficially owned | 0 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2015 | $328,148 | · | · | · | · | · | $1,447,371 | $1,841,519 |
| 2014 | $515,000 | $129,532 | · | · | · | · | $10,775 | $1,677,307 |
| 2013 | $500,000 | $187,500 | · | · | · | · | $11,868 | $699,368 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.